P15.02 Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer

PD-1/PD-L1 inhibitors as neoadjuvant therapy have shown promising anti-tumor activities in patients with early-stage non-small cell lung cancer (NSCLC). Here, we designed a phase II, single-arm trial to explore the antitumor activity, safety, and feasibility of neoadjuvant toripalimab plus double platinum-based chemotherapy in treatment-naive patients with potentially resectable NSCLC (ClinicalTrials.gov: NCT04144608).